Mesenchymal stem cells therapy (Therapeutic Solutions International)
- Generic Name
- Mesenchymal stem cells therapy (Therapeutic Solutions International)
Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease
- Conditions
- Crohn DiseaseCrohn Disease of VulvaRectolabial; FistulaRectovaginal Fistula
- Interventions
- Other: Placebo
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Amy Lightner
- Target Recruit Count
- 40
- Registration Number
- NCT04519697
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2024-07-26
- Target Recruit Count
- 45
- Registration Number
- NCT04506073
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Mesenchymal Stem Cell Infusion for COVID-19 Infection
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Dr. Zaineb Akram
- Target Recruit Count
- 20
- Registration Number
- NCT04444271
- Locations
- 🇵🇰
NIBMT, Rawalpindi, Punjab, Pakistan
Mesenchymal Stem Cells in the Treatment of Subjects with Advance Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 15
- Registration Number
- NCT04047810
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
The Maximum Tolerated Dose of Mesenchymal Stem Cells From Umbilical Cord
- Conditions
- Knee OsteoarthritisUmbilical Cord Bleeding
- Interventions
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT03357770
Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)
- Conditions
- Nephrotic SyndromeRenal Insufficiency, Chronic
- Interventions
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 116
- Registration Number
- NCT02966717
- Locations
- 🇨🇳
Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
MEsenchymal StEm Cells for Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Suspension media
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 1
- Registration Number
- NCT02403947
- Locations
- 🇫🇷
Purpan Hospital, Toulouse, France
Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Shaoxing Second Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT01902082
- Locations
- 🇨🇳
Shaoxing Second Hospital, Shaoxing, Zhejiang, China
Stem Cells in Rapidly Evolving Active Multiple Sclerosis
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 21
- Registration Number
- NCT01606215
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
Mesenchymal Stem Cells in Critical Limb Ischemia
- Conditions
- Critical Limb Ischemia
- Interventions
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2013-03-05
- Lead Sponsor
- Stempeutics Research Pvt Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT00883870
- Locations
- 🇮🇳
Amrita Institute of Medical Sciences, Kochi, Kerala, India
🇮🇳M.S.Ramaiah Memorial Hospital, Bangalore, Karnataka, India
🇮🇳Bhagawan Mahaveer Jain Heart Centre, Bangalore, Karnataka, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.